At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 82 enrolled
Drug / intervention
RV299 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A RANDOMISED, PHASE 1B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF RV299 AGAINST RESPIRATORY SYNCYTIAL VIRUS IN THE VIRAL CHALLENGE MODEL
In Brief
A Phase 1 clinical trial evaluating RV299 and Placebo for Respiratory Syncytial Virus (RSV). Completed, enrolled 82 participants across 1 site.
Detailed Summary
The purpose of the study is to learn about the safety, pharmacokinetics and antiviral activity of the study medicine (RV299) for the potential treatment of respiratory syncytial virus (RSV). RSV is a highly contagious virus that can lead to serious lung infections in patients with reduced ability to fight infection. Most vulnerable populations include babies, the elderly and patients that have received a bone marrow transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus (RSV)
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartAug 2022
Primary CompletionDec 2022
First PostedOct 2023
TodayJul 2026
First PostedOct 4, 2023
Enrollment StartAug 8, 2022
Primary CompletionDec 2, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.7 years ago
Interventions
RV299drug
Oral Suspension
Placebodrug
matching placebo